Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients

The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20-30%), and the majority of patients eventually relapse. One strategy to improve their out...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchini, Elisa, Rusconi, Chiara, Levis, Mario, Ricci, Francesca, Santoro, Armando, Ricardi, Umberto, Volpetti, Stefano, Matrone, Fabio, di Russo, Anna, Caizzi, Manuela, Schiattarella, Anna, Zaja, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215529/
https://www.ncbi.nlm.nih.gov/pubmed/34221295
http://dx.doi.org/10.4081/hr.2021.9080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215529/
https://www.ncbi.nlm.nih.gov/pubmed/34221295
http://dx.doi.org/10.4081/hr.2021.9080

Ejemplares similares